Atomo Diagnostics (ASX:AT1) secured an agreement to supply its HIV self-test kit to UK-based Newfoundland Diagnostics, valued at AU$5.4 million over five years, according to a Tuesday filing with the Australian bourse.
The agreement, running until June 30, 2030, grants Newfoundland exclusive distribution rights for the company's tests in the UK and non-exclusive rights for the EU and Colombia, the filing said.
Atomo Diagnostics shares rose nearly 6% in midday trade Tuesday.
Price (AUD): $0.02, Change: $+0.0010, Percent Change: +5.56%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。